Overview Request Sample Pages Request Customization Download PDF
You are viewing: China Companion Diagnostics Market analysis
Part of: Companion Diagnostics Market (Global)

The China Companion Diagnostics Market was valued at $579.3 Million in 2026 and projected to reach to $908.9 Million by 2031, representing a compound annual growth rate of 15.8%. China's companion diagnostics market is positioned for sustained growth driven by government initiatives promoting precision medicine and increasing healthcare expenditure.

China Companion Diagnostics Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Companion Diagnostics Market Trends and Insights

  • This growth trajectory reflects China's increasing investment in precision medicine infrastructure and rising adoption of targeted therapies across oncology and other therapeutic areas.
  • China's healthcare system modernization and government support for diagnostic innovation are driving accelerated market penetration. The 15.8% compound annual growth rate in China significantly outpaces global benchmarks, underscoring the country's strategic focus on personalized medicine.
  • China's expanding pharmaceutical pipeline and growing patient awareness of companion diagnostic benefits are key catalysts.
  • By 2031, China is expected to solidify its position as a critical hub for companion diagnostics development and commercialization within the Asia Pacific region..

Key Market Statistics

  • CAGR (2026-2031) 15.8% CAGR
  • Market Size, 2026 ~USD 579.3 Million
  • Forecast, 2031 ~USD 908.9 Million
  • Country China

China Companion Diagnostics Market Overview

Rapid Market Expansion :

China's companion diagnostics market is projected to grow from USD 579.3 million in 2026 to USD 908.9 million by 2031, representing a robust 15.8% CAGR, outpacing the global growth rate of 12.9%.

Precision Medicine Investment :

China's government is significantly investing in precision medicine infrastructure and modernizing its healthcare system, creating favorable conditions for companion diagnostic adoption across oncology and other therapeutic areas.

Targeted Therapy Adoption :

Rising adoption of targeted therapies in China is driving demand for companion diagnostics, as healthcare providers increasingly recognize the need for biomarker testing to optimize treatment outcomes and reduce healthcare costs.

Healthcare System Modernization :

China's healthcare system transformation and government support for advanced diagnostic technologies are accelerating the integration of companion diagnostics into clinical practice and treatment protocols.

China Companion Diagnostics Market Dynamics

  • The country's expanding oncology patient population and growing awareness of personalized treatment approaches are creating significant opportunities for diagnostic innovation.
  • Healthcare providers are increasingly adopting companion diagnostics to improve treatment efficacy and patient outcomes. The market will benefit from China's strengthening regulatory framework for in vitro diagnostics and rising collaboration between domestic and international diagnostic companies.
  • Investment in genomic sequencing infrastructure and biomarker research will further accelerate market penetration.
  • By 2031, companion diagnostics are expected to become integral to China's precision medicine ecosystem, supporting the country's transition toward value-based healthcare delivery..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • China's companion diagnostics market will grow from $579.3M (2026) to $908.9M (2031) at a 15.8% CAGR, outpacing global growth rates.
      • China's precision medicine initiatives and government regulatory support are accelerating adoption of companion diagnostic testing.
      • China's oncology segment drives the majority of companion diagnostics demand, supported by rising cancer incidence and targeted therapy expansion.
      • China's healthcare infrastructure modernization and increasing biotech investment position the country as a key Asia Pacific growth engine through 2031.

      Companion Diagnostics Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment NEXT-GENERATION SEQUENCING (Technology)
      Forecast Period 2026–2031
      Growth Rate CAGR of 12.9% from 2026 to 2031
      Largest Segment CANCER (Indication)
      Market Size Base Year (Billions) ~USD 6.31 (2026)
      Revenue Forecast (Billions) ~USD 11.57 (2031)
      Segments Covered Product & Service, Technology, Indication, Type, Sample Type, End User

      China Companion Diagnostics Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Product & Service

      • Assays, Kits, And Reagents
      • Instruments & Systems
      • Software & Services

      By Technology

      • Immunohistochemistry
      • In Situ Hybridization
      • Next-Generation Sequencing
      • Other Technologies
      • Polymerase Chain Reaction

      By Indication

      • Cancer
      • Cardiovascular Diseases
      • Infectious Diseases
      • Neurological Diseases
      • Other Indications

      By Type

      • Blood Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
      • Other Cancer Types
      • Other Cancers

      By Sample Type

      • Blood Samples
      • Other Sample Types
      • Tissue Samples

      By End User

      • Contract Research Organizations
      • Other End Users
      • Pharmaceutical & Biopharmaceutical Companies
      • Pharmaceutical & Biotechnology Companies
      • Reference Laboratories

      Target Audience

      • Diagnostic Companies : In vitro diagnostic manufacturers and companion diagnostic developers need China market data to assess expansion opportunities, competitive positioning, and regulatory requirements for market entry.
      • Pharmaceutical & Biotech Firms : Drug developers require companion diagnostics market intelligence to understand biomarker testing adoption rates, treatment algorithm integration, and commercial opportunities for targeted therapies in China.
      • Healthcare Investors : Private equity, venture capital, and institutional investors need China-specific market forecasts and growth metrics to evaluate investment opportunities in precision medicine and diagnostic companies.
      • Hospital & Clinical Networks : Healthcare providers and hospital systems need market insights to plan companion diagnostic implementation, budget allocation, and integration into precision oncology and treatment protocols.
      • Government & Policy Makers : Healthcare regulators and government agencies require market data to inform precision medicine policy development, healthcare infrastructure investment, and diagnostic technology adoption strategies.

      Key Companies in the China Companion Diagnostics Market

      CompanyHQOwnershipStrongest segments
      CLARITY PHARMACEUTICALSAustraliaPublic CompanySAR-bisPSMA theranostic platform,SAR-Bombesin pan-cancer theranostics,SARTATE (SSTR2-targeted theranostics),
      FOUNDATION MEDICINEUnited StatesPrivate CompanyFoundationOne CDx (tissue-based solid tumor CGP),FoundationOne Liquid CDx (blood-based solid tumor CGP),Hematologic malignancy / sarcoma / other LDTs,
      GEUnited StatesPublic CompanyCommercial Engines & Services,Defense & Propulsion Technologies,
      GENOMIC HEALTH INCUnited StatesPrivate CompanyOncotype DX Breast Recurrence Score and related breast assays,Oncotype DX Colon and prostate cancer assays,Other genomic and emerging epigenomic decision-support services,
      MEDICAL & BIOLOGICAL LABORATORIES CO.JapanPrivate CompanyAllergy in vitro diagnostics,Autoimmune and skin disease diagnostics,COVID-19 and respiratory diagnostics,
      ROSETTA GENOMICSIsraelPublic CompanymicroRNA-based oncology tests (RosettaGX Cancer Origin, mi-KIDNEY, RosettaGX Reveal, mi-LUNG),FISH-based assays (UroVysion, ERG/PTEN, ALK/ROS1),PCR gene mutation analysis (bladder, lung, colon, melanoma),
      TOSOH CORPORATIONJapanPublic CompanyBasic chemicals and chlor-alkali (caustic soda, sodium bicarbonate, related),Vinyls and petrochemicals (VCM, ethylene, propylene, aromatics, EDC),Polymers and synthetic rubbers (EVA, PE, functional polymers, PVC pastes),
      DIASORINItalyPublic CompanyImmunodiagnostics (LIAISON XL / LIAISON XS),Molecular diagnostics (Simplexa, LIAISON PLEX assays),xMAP technology and other IVD solutions,
      GE HEALTHCAREUnited StatesPublic CompanyImaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS),
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products (lab, transfusion, molecular, point-of-care, rapid tests),Medical Devices (cardiovascular, diabetes care, neuromodulation, vascular, structural heart),Nutritional Products (pediatric, adult, infant formula),
      DANAHERUnited StatesPublic CompanyBiotechnology (Bioprocessing & Single-Use),Life Sciences Tools & Genomics,Diagnostics,
      GUARDANT HEALTHUnited StatesPublic CompanyGuardant360 portfolio (CDx, Liquid, Tissue),Shield colorectal cancer screening,Minimal residual disease and recurrence (Guardant Reveal),
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array-based instruments and consumables,
      BIOMéRIEUXFrancePublic CompanyBIOFIRE & SPOTFIRE multiplex/lowplex PCR,VITEK (2, MS, REVEAL) ID/AST systems,BACT/ALERT VIRTUO & blood culture,
      ICON PLCIrelandPublic CompanyFull-service clinical development (Phase I–IV, peri/post-approval),Functional service partnerships & contract staffing,Laboratory, bioanalytical, biomarker, and vaccine testing,
      MYRIAD GENETICS, INC.United StatesPublic CompanyHereditary and oncology diagnostics (MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Precise Tumor),Women’s health and reproductive genetics (Prequel, Foresight, SneakPeek, FirstGene),Pharmacogenomics and mental health (GeneSight Psychotropic),
      SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx and related),Coagulation diagnostics,Blood gas, electrolyte, and urinalysis systems,
      ABNOVA CORPORATIONTaiwanPublic CompanyAntibodies (mono/polyclonal, recombinant, circulating rare cell),Proteins/Peptides, Lysates/Slides, Beads/Dyes, Ab Arrays,Medical Diagnostic Instruments, Systems, and Automation,

      CLARITY PHARMACEUTICALS

      Clarity Pharmaceuticals is an Australian public company founded in 2010 that employs 88 people. The company operates in the pharmaceutical sector.

      FOUNDATION MEDICINE

      Foundation Medicine is a United States-based private company established in 2009 with 662 employees. The company operates in the pharmaceutical and biotechnology industry.

      GE

      GE is a United States public company founded in 1892 with 57,000 employees. The company is a diversified conglomerate operating across multiple industrial sectors.

      GENOMIC HEALTH INC

      Genomic Health Inc. is a United States-based private company founded in 2000 with 829 employees. The company operates in the genomics and biotechnology sector.

      MEDICAL & BIOLOGICAL LABORATORIES CO.

      Medical & Biological Laboratories Co. is a Japan-based private company founded in 1969 with 408 employees. The company operates in the medical and biological laboratory sector.

      ROSETTA GENOMICS

      Rosetta Genomics is an Israel-based public company established in 2000 with 86 employees. The company operates in the genomics and molecular diagnostics sector.

      TOSOH CORPORATION

      Tosoh Corporation is a Japan-based public company founded in 1935 with 14,850 employees. The company operates across multiple sectors including chemicals, pharmaceuticals, and diagnostics.

      DIASORIN

      DiaSorin is an Italy-based public company founded in 1968 with 3,242 employees. The company operates in the in vitro diagnostics sector.

      GE HEALTHCARE

      GE Healthcare is a United States-based public company founded in 2022 with 54,000 employees. The company operates in the healthcare technology and diagnostics industry.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company operates in life sciences, diagnostics, and applied chemical markets.

      QIAGEN

      QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees. The company operates in molecular diagnostics and life sciences research.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and software.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company operates in diagnostics, medical devices, pharmaceuticals, and nutrition.

      DANAHER

      Danaher is a United States-based public company founded in 1969 with 59,000 employees. The company operates across life sciences, diagnostics, environmental, and applied solutions sectors.

      GUARDANT HEALTH

      Guardant Health is a United States-based public company founded in 2011 with 2,498 employees. The company operates in precision oncology and liquid biopsy diagnostics.

      ILLUMINA, INC.

      Illumina, Inc. is a United States-based public company founded in 1998 with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.

      BIOMéRIEUX

      bioMérieux is a France-based public company founded in 1963 with 14,894 employees. The company operates in in vitro diagnostics and microbiology testing.

      ICON PLC

      ICON PLC is an Ireland-based public company founded in 1989 with 40,350 employees. The company provides clinical research and development services to the pharmaceutical and biotechnology industries.

      MYRIAD GENETICS, INC.

      Myriad Genetics, Inc. is a United States-based public company founded in 1991 with 2,700 employees. The company operates in molecular diagnostics and personalized medicine.

      SYSMEX CORPORATION

      Sysmex Corporation is a Japan-based public company founded in 1968 with 10,861 employees. The company operates in clinical laboratory diagnostics and life sciences.

      ABNOVA CORPORATION

      Abnova Corporation is a Taiwan-based public company founded in 2002. The company operates in the biotechnology and life sciences research sector.

      Reasons to Buy this Report

      • Market Size & Growth Data : Access precise valuation metrics for China's companion diagnostics market with detailed CAGR analysis (15.8%) and forecasts through 2031, enabling accurate investment and expansion planning.
      • Competitive Landscape Intelligence : Understand China-specific market dynamics, key players, and competitive positioning within the rapidly expanding precision medicine sector to identify partnership and acquisition opportunities.
      • Regulatory & Policy Insights : Gain comprehensive understanding of China's healthcare modernization initiatives, government support mechanisms, and regulatory framework for companion diagnostics to navigate market entry effectively.
      • Therapeutic Area Opportunities : Identify high-growth segments within oncology and other therapeutic areas in China where companion diagnostics adoption is accelerating, supporting targeted business development strategies.
      • Strategic Market Positioning : Leverage China-specific market intelligence to develop localized go-to-market strategies, forecast revenue potential, and align product portfolios with emerging precision medicine trends.

      Frequently asked questions

      What is the current size of China's companion diagnostics market?

      China's companion diagnostics market is valued at USD 579.3 million in 2026 and is projected to grow to USD 908.9 million by 2031.

      What is the growth rate for companion diagnostics in China?

      China's companion diagnostics market is expected to grow at a compound annual growth rate (CAGR) of 15.8% from 2026 to 2031.

      What are the primary drivers of growth in China's companion diagnostics market?

      Key drivers include China's precision medicine initiatives, government regulatory support, rising cancer incidence, expanding targeted therapy pipelines, and modernization of healthcare infrastructure.

      Which therapeutic areas dominate China's companion diagnostics market?

      Oncology is the dominant therapeutic area in China's companion diagnostics market, driven by high cancer prevalence and the rapid adoption of targeted cancer treatments.

      How does China's companion diagnostics growth compare to global trends?

      China's 15.8% CAGR significantly exceeds the global companion diagnostics CAGR of 12.9%, reflecting China's accelerated investment in precision medicine and diagnostic innovation.

      RESEARCH METHODOLOGY

      This study involved four major activities in estimating the current size of the companion diagnostics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

      Secondary Research

      Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and European Federation of Biotechnology,. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global companion diagnostics market, and the findings were validated through primary research.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

      Companion Diagnostics Market Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The global size of the companion diagnostics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      Companion Diagnostics Market Top Down and Bottom Up Approach

      Data Triangulation

      After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

      Market Definition

      A companion diagnostic (CDx) is an in vitro diagnostic (IVD) device that is used to make biomarker assessments to identify whether a patient with certain chronic diseases, such as cancer, infectious diseases, and cardiovascular diseases, could benefit from a particular drug provides information essential for the safe and effective use of a specific therapeutic product, particularly targeted therapies and biologics. These tests help identify patients who are most likely to benefit from a treatment, may experience adverse reactions, or require therapy selection based on biomarker or molecular profiling. The market includes assay kits, reagents, instruments, software, and laboratory testing services across technologies such as polymerase chain reaction, next-generation sequencing, immunohistochemistry, and in situ hybridization, among others.

      Key Stakeholders

      • Manufacturers and Distributors of Companion Diagnostics Products
      • In Vitro Diagnostic (IVD) Companies
      • Hospital Laboratories
      • Diagnostic Laboratories
      • Diagnostics Suppliers
      • Pharmaceutical Companies
      • Research Laboratories and Academic Institutes
      • Clinical Research Organizations (CROs)
      • Research & Development (R&D) Companies
      • Academic Medical Centers/Government Research Organizations
      • Companion Diagnostics Service Providers
      • Government Associations
      • Market Research & Consulting Firms
      • Venture Capitalists & Investors

      Report Objectives

      • To define, describe, segment, and forecast the global companion diagnostics market, by product & service, technology, Indication, Sample type, Drug Class Associated with CDX, Application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall companion diagnostics market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to six regions: North America(US and Canada), Europe (Germany, France, the UK, Switzerland Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC and the Rest of Middle East], and Africa
      • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, collaborations, expansions, and other developments
      • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the report:

      Geographical Analysis

      • Further breakdown of the Rest of Europe companion diagnostics market, by country
      • Further breakdown of the Rest of Asia Pacific companion diagnostics market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Segment Analysis

      • Cross-segment analysis

       

      Get the Full Companion Diagnostics Market Report

      Full forecast, segment splits, and company analysis for all Companion Diagnostics Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status